New stent shows promise in Real-World heart patients

NCT ID NCT05677711

Completed Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 204 people with coronary artery disease who received the Ultimaster stent, a thin mesh tube coated with a drug that slowly releases to prevent arteries from clogging again. The stent's coating dissolves over 3-4 months. Researchers tracked safety and effectiveness over one year, looking at heart-related deaths, heart attacks, and the need for repeat procedures. The goal was to see how well the stent works in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ultimaster sirolimus-eluting coronary stent (a mesh tube coated with a drug that prevents artery re-blockage)
What this could lead to: If successful, this could confirm that the Ultimaster stent is a safe and effective option for treating blocked heart arteries in a wide range of patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. The stent still carries risks like blood clots or artery re-narrowing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE DRUG-ELUTING STENTS

Contacts and locations

Locations

Yongin Severance Hospital

Yongin, Gyeonggi-do, 16995, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.